<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied immunohistochemically the expression pattern of a neural cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule, L1, in various human migration disorders associated with <z:hpo ids='HP_0002126'>polymicrogyria</z:hpo>: 4 fetuses and 11 infants having Fukuyama type <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> (FCMD) (4 cases), <z:e sem="disease" ids="C0043459" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="ZS|ZWS">Zellweger syndrome</z:e> (6) or thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (3) and intrauterine brain damages (2) at different development stages, comparing to age-matched controls </plain></SENT>
<SENT sid="1" pm="."><plain>There were different patterns of L1 expression, which suggested at least 3 pathogenetic mechanisms: high expression associated with neuoraxonal <z:hpo ids='HP_0001548'>overgrowth</z:hpo> (fetal FCMD and destructive event at intermigratory period); delayed expression with neuronal dysmaturation and dysmyelinogenesis (late infantile stage of <z:e sem="disease" ids="C0043459" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="ZS|ZWS">Zellweger syndrome</z:e>); no expression in toxic or destructive brain injury (<z:e sem="disease" ids="C0043459" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="ZS|ZWS">Zellweger syndrome</z:e> or destructive events at inter-or postmigratory periods) </plain></SENT>
</text></document>